Patients who received MBTF prior to allo-HSCT achieved promising survival outcomes and manageable safety in relapsed/refractory acute myeloid leukemia.
Commentary|Articles|December 3, 2025
Lower-Intensity Regimens and CAR T-Cell Advances Drive Progress in AML and ALL at ASH 2025
Author(s)Ashling Wahner
Fact checked by: Chris Ryan
Hematology experts share the AML and ALL abstracts they’re most looking forward to seeing at the 2025 ASH Annual Meeting.
Advertisement
Advertisement
Research advances with azacitidine (Vidaza)/venetoclax (Venclexta)–based regimens in acute myeloid leukemia (AML) and CAR T-cell therapies in acute lymphoblastic leukemia (ALL) are set to steal the show during the
Related to this article
The top 5 OncLive TV videos of the week cover insights in ovarian cancer, breast cancer, head and neck cancer, pancreatic cancer, and follicular lymphoma.
Faculty convened for a virtual OncLive Scientific Interchange and Workshop to interpret emerging trial data and treatment strategies for systemic mastocytosis.
Peter Voorhees, MD, discusses the integration of CAR T-cell therapy in early-relapsed myeloma and the importance of early T-cell–redirecting therapy use.
Peter WT Pisters, MD, MHCM, will retire as president of The University of Texas MD Anderson Cancer Center.
The FDA has granted fast track designation to varsetatug masetecan for relapsed/refractory metastatic colorectal cancer.
SYS6090, a first-in-class PD-1/IL-15 bispecific fusion protein, earned fast track status for MSS/pMMR metastatic colorectal cancer that has progressed on standard systemic therapy.
Cathy Eng, MD, FACP, FASCO, discusses how oncology fellows can navigate the journal submission and review process.
Advertisement
Advertisement